• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

作者信息

Kelly Kaitlin, Cooperrider Jennifer H, Bishop Michael R, Kosuri Satyajit, Jakubowiak Andrzej, Derman Benjamin A

机构信息

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL.

The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL.

出版信息

Blood Adv. 2025 Jul 22;9(14):3613-3616. doi: 10.1182/bloodadvances.2024015721.

DOI:10.1182/bloodadvances.2024015721
PMID:40334078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281119/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/88b4c4f54559/BLOODA_ADV-2024-015721-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/88b4c4f54559/BLOODA_ADV-2024-015721-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg

相似文献

1
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.用于cilta-cel相关运动和神经认知毒性的鞘内化疗
Blood Adv. 2025 Jul 22;9(14):3613-3616. doi: 10.1182/bloodadvances.2024015721.
2
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.化疗诱导的 cilta-cabtagene autoleucel 相关运动和神经认知毒性逆转。
Blood. 2023 Oct 5;142(14):1248-1252. doi: 10.1182/blood.2023021429.
3
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.美国用嵌合抗原受体 T 细胞疗法 cilta-cabtagene autoleucel 和 idecabtagene vicleucel 治疗成人复发性或难治性多发性骨髓瘤的经济负担。
BioDrugs. 2022 Nov;36(6):773-780. doi: 10.1007/s40259-022-00557-3. Epub 2022 Sep 27.
4
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.病例报告：使用多巴胺能药物联合方案治疗 cilta-cabtagene autoleucel 引起的帕金森病。
Front Immunol. 2024 Sep 20;15:1444010. doi: 10.3389/fimmu.2024.1444010. eCollection 2024.
5
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.cilta-cel（西达基奥仑赛）治疗复发或难治性多发性骨髓瘤的CARTITUDE-1研究的通俗易懂总结
Future Oncol. 2023 Jun;19(18):1235-1247. doi: 10.2217/fon-2023-0270. Epub 2023 Jul 5.
6
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.西达基奥仑赛与标准治疗方案用于既往治疗过的复发或难治性多发性骨髓瘤患者的疗效比较：一项匹配调整间接比较
Adv Ther. 2025 May 12. doi: 10.1007/s12325-025-03205-8.
7
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.来那度胺难治性多发性骨髓瘤患者接受西达基奥仑赛或标准治疗后的患者报告结局（CARTITUDE-4）：一项随机、开放标签的3期试验结果
Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.
8
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.标准治疗方案西达基奥仑赛治疗复发/难治性多发性骨髓瘤的安全性和有效性
Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945.
9
Ciltacabtagene autoleucel (Carvykti) for multiple myeloma.西达基奥仑赛（Carvykti）用于治疗多发性骨髓瘤。
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e188-e189.
10
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma.在接受过大量预处理的复发或难治性多发性骨髓瘤患者中，使用西达基奥仑赛（ciltacabtagene autoleucel）后出现的血细胞减少和感染。
Haematologica. 2025 Jul 10. doi: 10.3324/haematol.2025.287783.

本文引用的文献

1
Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy.与抗B细胞成熟抗原嵌合抗原受体T细胞疗法相关的帕金森综合征
Mov Disord Clin Pract. 2024 Dec;11(12):1625-1628. doi: 10.1002/mdc3.14239. Epub 2024 Oct 21.
2
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.病例报告：使用多巴胺能药物联合方案治疗 cilta-cabtagene autoleucel 引起的帕金森病。
Front Immunol. 2024 Sep 20;15:1444010. doi: 10.3389/fimmu.2024.1444010. eCollection 2024.
3
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
标准治疗方案西达基奥仑赛治疗复发/难治性多发性骨髓瘤的安全性和有效性
Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945.
4
Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel.接受idecabtagene-vicleucel治疗的女性患者出现帕金森样神经毒性。
Hemasphere. 2024 Jul 25;8(7):e131. doi: 10.1002/hem3.131. eCollection 2024 Jul.
5
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.BCMA CAR-T 治疗后绝对淋巴细胞计数是复发多发性骨髓瘤患者反应和结局的预测因子。
Blood Adv. 2024 Aug 13;8(15):3859-3869. doi: 10.1182/bloodadvances.2023012470.
6
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?胰高血糖素样肽-1 类药物在帕金森病和阿尔茨海默病临床试验中显示出明确的保护作用：即将引发一场革命？
Neuropharmacology. 2024 Aug 1;253:109952. doi: 10.1016/j.neuropharm.2024.109952. Epub 2024 Apr 25.
7
BCMA-CAR T-cell treatment-associated parkinsonism.与BCMA嵌合抗原受体T细胞治疗相关的帕金森症
Blood. 2023 Oct 5;142(14):1181-1183. doi: 10.1182/blood.2023021860.
8
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.化疗诱导的 cilta-cabtagene autoleucel 相关运动和神经认知毒性逆转。
Blood. 2023 Oct 5;142(14):1248-1252. doi: 10.1182/blood.2023021429.
9
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
10
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?中枢神经系统血液疾病中CAR T细胞相关神经毒性：它仍然是一个需要关注的问题吗？
Front Neurol. 2023 Apr 6;14:1144414. doi: 10.3389/fneur.2023.1144414. eCollection 2023.